Divine Aleru, Microbiome Signatures Research Coordinator

This review highlights lactoferrin’s role as a biomarker for BD, D, and ED, and evaluates current detection technologies. It emphasizes F’s dual function in host defense and microbiome support.

This review explores lactoferrin’s multifaceted biological roles, emphasizing its ability to shape the microbiome, support immunity, and suppress inflammation and tumors.

This review explores lactoferrin’s biological roles, from microbiome modulation and immune defense to chronic disease and cancer prevention, supporting its use as a multifunctional therapeutic.

This review explores lactoferrin’s protective, antimicrobial, and immunomodulatory roles across life stages, highlighting its impact on the gut microbiome, disease prevention, and aging-related health.

Prebiotic Maltose Gel has emerged as a promising microbiome-targeted therapy for bacterial vaginosis (V), restoring vaginal health by selectively enhancing Lactobacillus populations and suppressing V-associated anaerobes. This dual-action intervention not only validates the gel’s therapeutic efficacy but also confirms the accuracy of V’s microbiome signature as a clinical marker.

Probiotic interventions, particularly those involving Lactobacillus crispatus and Saccharomyces cerevisiae, restore balance to the vaginal microbiome in bacterial vaginosis (V). By reducing dominant anaerobes like Gardnerella vaginalis and promoting recolonization with protective Lactobacillus, these therapies validate both their role as microbiome-targeted interventions (BTIs) and the diagnostic accuracy of the V microbiome signature.

Essential oils (Os) are emerging as powerful microbiome-targeted interventions for biofilm-associated infections (AIs). Backed by preclinical evidence, Os disrupt biofilm formation, reduce inflammation, and restore microbial balance. This validation supports their dual role in treating AIs and confirming the microbiome signature linked to the condition.

Bovine lactoferrin has emerged as a promising microbiome-targeted intervention (BTI) for bacterial vaginosis (V). Clinical and preclinical studies confirm its dual-action ability to restore Lactobacillus dominance and suppress V-associated pathogens like Gardnerella and Prevotella. These microbial shifts, combined with anti-inflammatory effects, validate both the efficacy of bovine lactoferrin and the diagnostic accuracy of the V microbiome signature.

Vitamin C vaginal tablets represent a compelling microbiome-based therapy for recurrent bacterial vaginosis. By restoring vaginal pH and supporting Lactobacillus reestablishment, this intervention validates both its therapeutic role and the microbial signature of V.

Tinidazole is a validated microbiome-targeted therapy for bacterial vaginosis, restoring microbial balance and aligning with diagnostic signatures. It offers better tolerability than metronidazole, with fewer side effects and strong clinical outcomes.